Open-ended concept elicitation with breast cancer (BC) patient advocates to inform patient-reported outcome (PRO) endpoints in neoadjuvant and adjuvant trials of trastuzumab emtansine (T-DM1)

MLA

Mary Lou Smith, et al. “Open-Ended Concept Elicitation with Breast Cancer (BC) Patient Advocates to Inform Patient-Reported Outcome (PRO) Endpoints in Neoadjuvant and Adjuvant Trials of Trastuzumab Emtansine (T-DM1).” Journal of Clinical Oncology, vol. 31, Sept. 2013, p. 172. EBSCOhost, https://doi.org/10.1200/jco.2013.31.26_suppl.172.

APA

Mary Lou Smith, Joan Venticinque, Ellie Guardino, Kimberly Sabelko, Jenna Glazer, Hope Wohl, A. Campbell, & Elyse S. Caplan. (2013). Open-ended concept elicitation with breast cancer (BC) patient advocates to inform patient-reported outcome (PRO) endpoints in neoadjuvant and adjuvant trials of trastuzumab emtansine (T-DM1). Journal of Clinical Oncology, 31, 172. https://doi.org/10.1200/jco.2013.31.26_suppl.172

Chicago

Mary Lou Smith, Joan Venticinque, Ellie Guardino, Kimberly Sabelko, Jenna Glazer, Hope Wohl, A. Campbell, and Elyse S. Caplan. 2013. “Open-Ended Concept Elicitation with Breast Cancer (BC) Patient Advocates to Inform Patient-Reported Outcome (PRO) Endpoints in Neoadjuvant and Adjuvant Trials of Trastuzumab Emtansine (T-DM1).” Journal of Clinical Oncology 31 (September): 172. doi:10.1200/jco.2013.31.26_suppl.172.